{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408926585
| IUPAC_name = (2''S'')-2-Ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)<br />ethoxy]phenyl]propanoic acid
| image = Tesaglitazar.svg
| width = 275

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Development terminated
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 251565-85-2
| ATC_prefix = None
| ATC_suffix =
| PubChem = 208901
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 6734037O3L
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01274
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 521632
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 180999

<!--Chemical data-->
| C=20 | H=24 | O=7 | S=1 
| molecular_weight = 408.46 g/mol
| smiles = CCO[C@@H](CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = CXGTZJYQWSUFET-IBGZPJMESA-N
}}

'''Tesaglitazar''' (also known as '''AZ 242''') is a dual [[PPAR agonist|peroxisome proliferator-activated receptor agonist]] with affinity to [[Peroxisome proliferator-activated receptor alpha|PPARα]] and [[Peroxisome proliferator-activated receptor gamma|PPARγ]], proposed for the management of [[Diabetes mellitus type 2|type 2 diabetes]].<ref name="pmid17907109">{{cite journal |vauthors=Wilding JP, Gause-Nilsson I, Persson A |title=Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes |journal=Diab Vasc Dis Res |volume=4 |issue=3 |pages=194–203 |year=2007 |pmid=17907109 |doi=10.3132/dvdr.2007.040}}</ref>

The drug had completed several [[clinical trial#Phase III|phase III clinical trial]]s,<ref name="title">{{cite web | url = http://www.astrazenecaclinicaltrials.com/ncmprintchapter.aspx?type=article&param=520974 | title = GALIDA (tesaglitazar) Clinical Trial Report Summaries | accessdate = 2008-03-17 | author = | date = | work = | publisher = AstraZeneca | pages = }} {{Dead link|date=October 2010|bot=H3llBot}}</ref> however in May, 2006  [[AstraZeneca]] announced that it had discontinued further development.<ref name="AstraZeneca_tesaglitazar_press_release)">{{cite web | url = http://www.astrazeneca.com/Media/Press-releases/Article/20060504--AstraZeneca-Discontinues-Development-of-GALIDA-TM-te | title = AstraZeneca Discontinues Development of GALIDA (tesaglitazar) | accessdate = 2012-07-23 | author = | date = 2006-05-04 | work = | publisher = AstraZeneca  | pages = }}</ref>

==References==
{{Reflist|2}}

{{Oral hypoglycemics and insulin analogs}}
{{PPAR modulators}}

[[Category:Abandoned drugs]]
[[Category:Carboxylic acids]]
[[Category:Phenol ethers]]
[[Category:PPAR agonists]]
[[Category:Sulfones]]

{{gastrointestinal-drug-stub}}